BerGenBio ASA is focusing its efforts on addressing the unmet medical need in STK11-mutated non-small cell lung cancer (NSCLC) with its selective AXL inhibitor, bemcentinib. The company's Q3 2024 earnings call highlighted the potential of bemcentinib in this specific patient population, alongside news of a leadership transition.
Clinical Progress and Regulatory Status
BerGenBio's lead candidate, bemcentinib, has received fast-track designation from the FDA, a move that could accelerate its path to market. This regulatory support underscores the urgency of addressing STK11-mutated NSCLC, a subtype associated with poorer prognosis. The company has built a robust safety database, with its molecule studied in over 600 patients across various trials.
The ongoing BTBC 16 study is evaluating bemcentinib in STK11-mutated NSCLC. Interim data from the study is anticipated in early 2025, while the final data readout, which includes two years of patient follow-up, could extend to 2026. These timelines are contingent on data maturity and patient follow-up durations.
Strategic Adjustments and Pipeline Focus
BerGenBio has made strategic decisions to streamline its pipeline. The Sylvest program was discontinued due to a lack of viable partnership opportunities. Additionally, the ADC 601 program, partnered with ADC Therapeutics, faced setbacks due to a narrow therapeutic window, leading to its discontinuation.
Leadership Transition
CEO Martin Olin will be leaving BerGenBio for an external opportunity. To ensure continuity, Olin will remain in his role until a new CEO is appointed. The company has added David Coldman to its board, bringing expertise in business development and licensing from the pharmaceutical and biotech sectors.
Financial Stability
BerGenBio reports a stable financial position, with sufficient cash reserves to fund operations into the third quarter of 2025. This financial runway provides the company with the resources to advance its clinical programs and pursue strategic objectives.
